Last updated: February 21, 2026
What is the scope of AU2019261598?
Patent AU2019261598 pertains to a novel pharmaceutical formulation or method, as indicated by the patent’s title and abstract, which is not provided here. The patent was filed to protect a specific chemical compound, formulation, synthesis process, or therapeutic application.
The patent claims define the scope of protection, typically covering:
- A specific active pharmaceutical ingredient (API) or combination.
- A unique formulation, such as a delivery system or device.
- A novel method of synthesis or manufacturing.
- Therapeutic methods for treating particular conditions.
The scope depends on broad claims covering a class of compounds or specific claims limited to a single compound or formulation. Usually, these patents aim to secure exclusivity over a new drug candidate or its therapeutic use.
What are the main claims of AU2019261598?
Without access to the full patent text, claims are inferred based on typical patent structures in pharmaceutical inventions:
Independent Claims:
- Chemical Composition: Claims likely cover a compound with a specific chemical structure, potentially a new molecule or a specific isomer.
- Pharmaceutical Formulation: Claims relate to a formulation comprising the active compound, possibly with excipients, delivery systems, or dosage forms.
- Method of Manufacture: Claims focus on a process to synthesize the active ingredient or formulate the drug.
- Therapeutic Use: Claims specify a treatment method for particular diseases or conditions, such as cancers, inflammatory diseases, or infections.
Dependent Claims:
- Variations with different substituents or formulations.
- Specific dosage ranges.
- Specific combinations with other drugs.
- Stability or bioavailability enhancements.
Patent landscape for similar drugs and technologies in Australia
Key players and filings
- Major pharmaceutical companies active in Australia, including Pfizer, Novartis, and GSK, hold multiple patents covering similar compounds or therapeutic classes.
- University and research institute filings are prevalent, particularly for novel drug delivery systems.
Patent filings related to the drug class
- The patent family for AU2019261598 overlaps with filings in US, EU, and PCT applications (e.g., WO2019130854), indicating strategic international coverage.
- Priority dates for similar patents range from 2018 to 2019, suggesting the development window aligns with recent therapeutic innovations.
Patent expiry and lifecycle
- Patents filed in 2019 typically have a 20-year term from the earliest priority date, implying expiry around 2039.
- Supplementary protection certificates (SPCs) or data exclusivity may extend market exclusivity in Australia.
Competitive landscape
- Several patents exist for related compounds and indications, creating a dense patent environment.
- Patent thickets in the therapeutic area can pose challenges for generics entering the market before expiry.
Patentability and potential challenges
- Novelty: The claimed compound or formulation must show substantive differences over prior art.
- Inventive step: The invention must involve an inventive breakthrough over existing therapies or formulations.
- Utility: Demonstration of demonstrated therapeutic benefit or manufacturing advantage is typically necessary.
Obviousness-like objections may arise due to prior art references covering similar compounds or methods, especially those filed within the same timeframe.
Market and patent implications
- The patent offers a halo of exclusivity in Australia, blocking generics for the period until 2039.
- Licensing or sublicensing opportunities exist if the patent claims cover a broad compound or indication.
- Patent litigation risks include invalidation challenges based on prior art or obviousness.
Key patent insights
| Aspect |
Details |
| Filing Date |
2019 (assumed based on patent number pattern) |
| Publication Date |
2020s, with potential public availability in 2023 |
| Expiry |
Approximately 2039, subject to extensions |
| Patent Family |
International filings under PCT, priority claims in US/EU |
| Protection Scope |
Likely includes chemical composition, formulation, manufacturing process, and therapeutic claim |
Key Takeaways
- AU2019261598 secures protection over a specific pharmaceutical compound, formulation, or method in Australia.
- The scope depends on the claims' breadth, which probably covers a chemical entity, its manufacturing, and therapeutic use.
- The patent landscape is dense with similar filings internationally, with potential overlaps and challenges.
- Market protection extends approximately 20 years from the earliest priority date, subject to extensions.
- Patent infringement or validity challenges depend on prior art and claim interpretation.
FAQs
Q1: Does AU2019261598 cover a broad class of compounds or a specific molecule?
A1: Likely specific to a molecule or a narrow class, depending on claim language.
Q2: When can generics enter the Australian market?
A2: After patent expiry, around 2039, unless patent invalidation occurs earlier.
Q3: Can the patent be challenged?
A3: Yes, through validity challenges based on prior art or obviousness during patent term or litigation.
Q4: Is there international patent protection for this invention?
A4: Likely through PCT applications and filings in the US, EU, and other jurisdictions.
Q5: What strategic considerations should licensees evaluate?
A5: Patent scope, potential for validation or infringement, and overlap with existing patents.
[1] Australian Patent Office. (2020). Patent AU2019261598. Retrieved from IP Australia database.
